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 Abstract 
Background: Cardiovascular diseases (CVDs) continues to be the leading cause of death 
worldwide. A fixed-dose combination therapy (“polypill” strategy) was proposed as a cost-
saving method for CVD prevention, especially in lower resource settings. We conducted the 
PolyIran Study to assess the effectiveness and safety of a four-component polypill including 
aspirin, atorvastatin, hydrochlorothiazide and either enalapril or valsartan, for primary and 
secondary prevention of CVD.  
Methods: The PolyIran study is a two-arm pragmatic cluster randomized trial nested within 
the Golestan Cohort Study (GCS). The sampling frame for the PolyIran study was rural GCS 
participants aged 50 years or older. Considering villages as clusters, and using a cluster 
randomization, the study participants were allocated to a package of non-pharmacological 
preventive interventions either alone (minimal care arm) or together with a once daily 
polypill (polypill arm). All participants were followed for 60 months and the primary 
outcome was occurrence of major cardiovascular events (MCVE). The risk of MCVE 
between the two arms was compared using Cox regression models, with shared frailty 
models.  
Findings: Overall, 6841 individuals were enrolled in the study, including 3,417 (in 116 
clusters) in the minimal care arm and 3,421 (in 120 clusters) in the polypill arm. Median 
(interquartile range) adherence to polypill tablets was 80.5% (48.5-92.2). During the follow 
up, 202 and 301 participants in the polypill arm and minimal care arm respectively had one or 
more MCVE, representing a 34% reduction (adjusted hazard ratio [HR]=0.66; 95% 
confidence interval [CI]: 0.55-0.80) in risk of MCVE in the polypill arm. The risk of MCVE 
in participants with high adherence was significantly lower when compared with the minimal 
care arm (adjusted HR=0.43; 95%CI: 0.33-0.55). The effect of polypill was stronger in 
participants without pre-existing CVD (primary prevention group) (HR=0.61, 95% CI:  0.49-
0.75) than those with history of CVD (secondary prevention group) (HR=0.80, 95% CI: 0.57-
1.12) (p-value for interaction=0.19). Overall, the frequency of adverse events was 
comparable between the two arms. 
Interpretation: The PolyIran study is the first large scale pragmatic trial with long term 
follow up demonstrating the effectiveness of a fixed-dose combination therapy in primary 
and secondary prevention of CVDs. Our results showed high medication adherence and the 
risk of adverse events was similar between the two arms. The polypill strategy may be 
considered as an additional effective component in controlling CVDs, especially in low 
resources settings. 
Key words: Cardiovascular Diseases, Primary Prevention, Secondary Prevention, Fix 
dose combination Drug Therapy     
Funding: This study was funded by Tehran University of Medical Sciences, Tehran, 
Iran. 
Trial registration: The protocol of the PolyIran study was registered with 
clinicaltrials.gov, number NCT01271985. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction: 
Cardiovascular diseases (CVDs) are the main cause of death and a major cause of health loss 
worldwide with estimated 422.7 million prevalent cases and 17.92 million deaths in 20151 
and a 16% increase in disability-adjusted life years (DALYs) during the last decade.2 The 
highest age standardized prevalence of CVDs was found in West Africa, Morocco, Iran, 
Oman, Zambia, Mozambique, and Madagascar.1 The age standardized disability-adjusted life 
years (DALYs) rates of CVD was considerably higher in the Eastern Mediterranean Region 
(EMR) than in other regions,3 suggesting greater burden of CVD in low-resources settings. 
Data from the GBD project suggest that according to current trends, the United Nation 
Sustainable Development Goal (SDG) to reduce premature mortality due to CVD by a third 
in 2030 will not be possible for majority of low- and middle-income countries (LMICs).4-6 
Ischemic heart disease (IHD) and stroke are the primary causes of death among middle aged 
and older Iranian adults and occur at a relatively younger age in Iran compared to high-
income countries.7,8 The Golestan Cohort Study (GCS)9 is the largest prospective study in 
central and Western Asia and was primarily intended to study the etiology of very prevalent 
esophageal cancer in Northeastern Iran. However, it revealed that 63.3% of all deaths 
occurred prematurely with IHD accounting for 33.9% of all premature deaths, followed by 
stroke (14.0%). The results of the GCS also suggested that 30% and 64% of all CVD-related 
deaths were occurred in participants below 60 and 70 years old, respectively.7 
The strategy of a fixed-dose combination therapy (“polypill” ) administered to asymptomatic 
adults was proposed to increase adherence10,11 and it was believed that it could reduce CVD 
by more than 80%.12 It is also cost-saving when compared to usual care.13 Different 
formulations of polypill were used in several studies worldwide.14-21 The results of a pilot 
study from Iran suggested that a polypill consisted of aspirin 81 mg, enalapril 2.5 mg, 
atorvastatin 20 mg and hydrochlorothiazide 12.5 mg was well tolerated and participants' 
compliance to the polypill was satisfactory, with modest reductions in blood pressure and 
lipid levels.22 It also confirmed the feasibility of a fully powered trial to investigate the 
impact of the polypill on major cardiovascular events (MCVE). Therefore, the PolyIran study 
was designed to assess the effectiveness of a four-component polypill including aspirin (80 
mg), atorvastatin, (20 mg), hydrochlorothiazide (12.5 mg) and either enalapril (5 mg) or 
valsartan (40 mg), together with advice on lifestyle modification for primary and secondary 
prevention of CVD compared with  advice on lifestyle modification alone.    
  
Methods: 
Study setting and sampling frame:  
The PolyIran study is a two-arm pragmatic cluster randomized trial nested within the 
Golestan cohort study (GCS),9 a cohort study with 50,045 participants aged 40-75 years from 
Golestan province in northern Iran. Twenty percent of the GCS participants were enrolled 
from Gonbad city and 80% from rural areas covering the villages in Gonbad, Aq-Qala and 
Kalaleh districts. The main aim of the GCS was to investigate esophageal cancer risk factors 
in this high-risk area. The sampling frame for the PolyIran study included the 28,660 GCS 
participants from rural areas (villages) aged 50 years and above in 2011 (the beginning of the 
study).  
Sample size justification: 
Given the MCVE rate of 0.0171 per year in the GCS (unpublished data), we anticipated the 
risk of an event to be approximately 0.077 over 5 years. With the available 262 clusters, with 
an average size of 28 individuals (22 after drop out), and using the upper estimate of the 
intra-cluster correlation (ICC) of 0.038, coefficient of variation of cluster size of 0.9, 
considering 80% power, at 5% significance, a clinically important effect size of 0.65 and 
20% loss to follow up, a total sample size of 7224 participants (3612 per arm) was calculated 
for the PolyIran study. 
Treatment arms, study population, and randomization: 
The study methods and design were described previously.23 Briefly, from the PolyIran 
sampling frame, 13,875 individuals were selected using a simple stratified random selection 
procedure weighted according to the number of eligible inhabitants in each village. These 
random samples from each village constituted the clusters (262 clusters). Villages (i.e. 
clusters) were then randomly allocated to a package of non-pharmacological preventive 
interventions either alone (minimal care arm; 6,883 individuals, 132 clusters) or together with 
a once daily polypill tablet (polypill arm; 6,992 individuals, 130 clusters). Accordingly, all 
participants within a cluster were randomized to receive the same intervention. Cluster 
randomization was used in this study to avoid issues of contamination that would be likely to 
arise due to sharing of medicines. 
Villages (clusters) that were hard to access were excluded from the PolyIran study. Table 1 
shows eligibility criteria at individual level.  
For the first 48 clusters enrolled in the study, the enrollment team was aware of the allocation 
of clusters, which resulted an imbalance in covariates and the proportion of ineligible 
participants between the polypill and minimal care arms. An interim analysis at this point 
demonstrated that the proportion of subjects who met the exclusion criteria differed between 
the polypill and minimal care arms, presumably due to preferential behavior of the enrolling 
physician applying the exclusion criteria more stringently to the polypill arm. After that 
point, there was full allocation concealment. Polypill tablets were since then provided by the 
Behvarz a few days after enrolment of the participants and the allocation of the clusters was 
thus concealed from the enrolment team members. To assess the effects of allocation 
concealment, we categorized study participants into two subgroups: those enrolled without 
allocation concealment and with allocation concealment. 
Of the 28,660 rural GCS participants aged 50 or older (PolyIran sampling frame), 14,785 
individuals were not considered to be randomized and thus were invited to participate in the 
PolyIran study. In addition, 5465 participants who were initially selected for random 
allocation in the two arms (2759 participants in polypill arm and 2706 participants in minimal 
care arm) did not attend eligibility check. These total 20,250 individuals who did not receive 
the interventions of the PolyIran study (neither polypill nor minimal care), were considered as 
an additional external, non-randomized comparison in the PolyIran study. They received 
usual care offered by the public and private sector, and hence were defined as “the usual care 
group”. 
Intervention: 
All participants in both arms received minimal care, a package of non-pharmacological 
interventions including educational training about a healthy lifestyle, including healthy diet 
with low salt, sugar and fat content, exercise, weight control and abstinence from smoking 
and opium. These interventions were delivered through face-to-face interview, by a short text 
messages (SMS) twice monthly and a pictorial pamphlet. The contents include educational 
training about a healthy lifestyle, including healthy food intake with low salt, sugar and fat 
content, exercise, weight control and abstinence from smoking and opium. All participants in 
both arms had also biannual blood pressure measurement and those identified as hypertensive 
were referred to their local family physicians for blood pressure control.  
In addition to minimal care, participants in the polypill arm who met the eligibility criteria 
received a polypill tablet. Two formulations of polypill tablet were used in this study (Alborz 
Darou Pharmaceutical Company, Tehran, Iran). Participants were first prescribed polypill 1, 
(hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg and enalapril 5 mg). Those 
who developed cough during follow-up were switched by the study physician to polypill 2, 
which substitutes enalapril 5 mg with valsartan 40 mg. 
The usual care group received neither polypill nor minimal care. They received only usual 
care offered by the public and private sector. 
Follow up:  
Field Follow-up visits were scheduled to occur at months 1, 2, 3, 6 and then 6 monthly in the 
polypill arm and at months 3, 6 and then 6 monthly in minimal care arm. At follow-up visits, 
all participants were offered minimal care, and in the polypill arm, tablets were dispensed and 
pill counts undertaken. Participants were interviewed to maintain study participation and to 
assess the presence of symptoms that might indicate adverse events. Participants who 
reported symptoms were first visited by the study physician and at the study physician’s 
discretion were referred to their local family physicians. 
Outcomes:  
The primary outcome is the occurrence of MCVE during 60 months after enrollment. MCVE 
included hospitalization for acute coronary syndrome (non-fatal myocardial infarction and 
unstable angina), fatal myocardial infarction, sudden death, heart failure, coronary artery 
revascularization procedures, and non-fatal and fatal stroke. For participants with more than 
one MCVE, the first event was included in the primary outcome analysis. Secondary 
outcomes were the components of the MCVE considered individually, non-cardiovascular 
causes of death (including neoplastic, respiratory, hepatic, renal and other medical causes), 
adherence to the polypill (based on pill count) and changes in blood pressure and low-density 
lipoprotein (LDL) cholesterol during the study. 
The study continued for 60 months. Participants who were lost to follow up, those who were 
still alive at month 60 and those who died from non-MCVE causes were censored. 
Outcome ascertainment was through the GCS follow up team and personnel responsible for 
outcome ascertainment were therefore independent of the PolyIran team and therefore blind 
to allocation status. Briefly, all GCS participants were contacted by telephone annually 
inquiring about health status and any admission to hospital or outpatient CVD clinics. On 
learning of a death or possible non-fatal CVD event, all relevant medical documents were 
collected by one of the study staff from hospitals or patients’ homes. Two separate internists 
then independently reviewed all documents and ascertained the outcome on the basis of 
standardized criteria. In case of discordance, the outcome was ascertained following review 
of all documents by a panel of expert cardiologists and internists. 
Statistical analysis:  
Analysis of primary outcomes: Analysis were done by intention to treat and all subjects 
who met the eligibility criteria were included. The null hypothesis (no difference) for the 
primary outcome were tested using a random effects Cox model with time to the primary 
outcome and censoring those who were lost to follow-up or who die from other causes. We 
used Cox regression models, with shared frailty to account for cluster randomization, to 
obtain hazard ratios (HR) and 95% confidence intervals (95%CI). Results of both unadjusted 
and adjusted models are presented. In addition, the clustering effects were also assessed using 
VCE option and the results were compared with those of frailty model. As described in the 
analysis plan, adjustments were done for age (in years), gender (male or female), history of 
MCVE, diabetes mellitus, and hypertension. Diabetes was defined as: self-report based on a 
physician diagnosis; fasting blood glucose ≥126 mg/dl; or use of anti-diabetes drugs. 
Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, diastolic blood 
pressure (DBP) ≥90 mmHg, physician-confirmed diagnosis of hypertension, or use of anti-
hypertensive drugs (in participants without history of CVD).  
Several prespecified subgroup analyses were performed by gender, age group, preexisting 
CVD, preexisting hypertension, preexisting diabetes mellitus, ethnicity, history of smoking, 
baseline cholesterol level, and adherence to polypill. Interaction terms were introduced in the 
models. For these analyses, age was categorized into two groups, ≤65 and >65 years. For 
cholesterol, the participants were categorized into ≤198 and >198 mg/dL groups. Adherence 
to polypill was measured using pill count, during each study visit and for the entire study 
period. If a participant could not be accessed in a follow up visit and no further information 
was available, adherence for that follow-up was coded as missing. The study participants 
were a priori categorized into three groups: high adherence (≥70%), medium adherence 
(50%-69%), and low adherence (<50%). As there were relatively few participants in the latter 
two groups (medium and low) and the participants in these two categories had similar 
characteristics and outcome, we merged them into a single group, and therefore the final 
categorization was dichotomized as high (≥70%) and medium/low adherence (<70%).  
Analysis of secondary outcomes: The risks of the components of MCVE (i.e., non-fatal 
myocardial infarction and unstable angina, fatal myocardial infarction, sudden death, heart 
failure, coronary artery revascularization procedures, non-fatal and fatal stroke), non-
cardiovascular mortality as well as overall mortality were compared between polypill and 
minimal care arms. For time to certain occurrence of secondary outcomes (e.g., time to 
death), unadjusted and adjusted HRs and the 95% CI were calculated using Cox regression 
analysis with frailty models. For continuous secondary outcomes (changes in blood pressure 
and LDL-cholesterol), data were analyzed using mixed effects linear regression models. Log 
transformations were considered for variables with non-normal distribution. To assess the 
association of adherence to polypill tablet with baseline covariates, odds ratios and 95% CIs 
were calculated using mixed effects logistic regression models.  
Analysis of adverse events: 
Data on adverse events were collected for all participants who attended the follow up visits. If 
a participant reported similar adverse events in more than one follow-up visit, the earliest 
date was taken into account. At the end of study (month 60 follow up visit), the study 
participants were asked about the occurrence of physician-confirmed diagnosis of selected 
conditions including peptic ulcer diseases and upper gastrointestinal bleeding.     
Additional comparison:  
The aim of additional comparison was to compare the HRs of MCVE in usual care group 
with those of polypill and minimal care arms. Usual care group participants were not assessed 
for eligibility criteria; hence it was not possible to determine eligible subjects in this group. 
Therefore, all eligible and ineligible participants in the polypill (n=4,233) and minimal care 
(n=4,177) arms were entered into the additional comparison. Since outcome ascertainment in 
all 20,250 would have been burdensome and expensive, a random sample of 4,305 
participants was selected from the usual care group using cluster randomization method, for 
whom complete outcome ascertainment was performed similar to study arms.  
Cox regression models were used to compare the HR of MCVE in usual care group with 
those of polypill and minimal care arms. As the usual care group members did not attend the 
eligibility check, there was no enrollment time for these participants. Therefore, we 
considered a fixed date (the date of enrollment of the first participant in the polypill or 
minimal care arms) as enrollment date for all usual care participants. As with previous 
analyses, Cox regression results were adjusted for clustering effects using shared frailty 
models.  
Ethical approval and Trial registration: 
The protocol of the PolyIran study was reviewed and approved by Institutional Review Board 
(IRB) of Digestive Diseases Research Institute and Tehran University of Medical Sciences 
and registered with clinicaltrials.gov (clinicaltrials.gov identifier: NCT01271985). 
Results: 
Main comparison 
Enrollment of study participants: A total of 6841 individuals were enrolled in the study, 
3,417 (in 116 clusters) in the minimal care arm and 3,421 (in 120 clusters) in the polypill 
arm. Further details are shown in the study flow chart (Figure 1) and in Supplementary Figure 
1. Figure 2 shows the time sequence of steps and blinding status in the PolyIran study. The 
allocation status was concealed to the enrolment team in the first 48 clusters (1,836 
participants) and the remaining 188 clusters (5,002 participants) were enrolled with allocation 
concealment (Table 2). 
Analysis of primary outcomes: The two study arms are reasonably balanced with respect to 
gender, history of pre-existing cardiovascular disease, hypertension, diabetes mellitus, 
smoking, age group, and other potential confounders. (Table 2)  
Table 3 shows the results of the primary and subgroup analyses. There were 202 MCVE 
during the 60 months in the polypill arms and 301 in the minimal care arm. There was a 34% 
reduction (adjusted HR=0.66; 95%CI: 0.55-0.80) in risk of MCVE in polypill arm when 
compared to minimal care arm. The corresponding Kapan-Meier curve is shown in Figure 3. 
The results using shared frailty models were very similar to those without frailty models, as 
were those using the VCE option in Stata (Supplementary Table 1). The number to treat (95% 
CI) to prevent one MCVE was 35 (95% CI: 24-60). 
The risk of MCVE in participants with high adherence to polypill tablet was significantly 
lower when compared with the minimal care arm (adjusted HR=0.43; 95%CI: 0.33-0.55), 
corresponding to a NNT of 21 (95%CI: 17-28) to prevent one MCVE. 
When stratified by age, gender, pre-existing MCVE, hypertension, diabetes mellitus, baseline 
cholesterol levels and smoking, there was no statistically significant difference in effect 
among the subgroups (Table 3). However, there was a non-significant stronger effect on 
primary (no prior MCVE) than secondary prevention (prior MCVE). See Table 3 and Figure 
4.   
Our findings suggested that a longer duration of polypill use was associated with a stronger 
protective effect of polypill use; the HR was considerably lower during the latter part of the 
follow up period (between month 37 and month 60) (HR=0.52; 95%CI:0.39-0.70) than the 
earlier parts of the study follow up period (Table 4).  
Analysis of secondary outcomes: The median (interquartile range) of adherence was 80.5% 
(48.5-92.2). The adherence levels were high, medium and low in 2,144 (62.7%), 405 (11.8%) 
and 872 (25.5%) participants. Figure 5 shows adherence levels in polypill participants by 
follow up month. Relationships between different covariates with high adherence 
(adherence≥70%) to polypill tablet are presented in Table 5. The proportion of participants 
with high adherence to polypill was significantly higher in men and those with pre-existing 
hypertension, and significantly lower in participants with preexisting CVD and smokers. 
Table 6 shows the risk of components of MCVE, non-MCVE mortality as well as overall 
mortality in the two arms. The risk of fatal (HR=0.51; 95%CI: 0.30-0.87) and non-fatal 
(HR=0.74;95%CI: 0.58-0.96) IHD as well as fatal (HR=0.38;95%CI: 0.18-0.82) and non-
fatal (HR=0.44;95%CI: 0.23-0.82) stroke was significantly lower in polypill arm. We found 
no significant differences in the risk of overall mortality, non-MCVE mortality, sudden death 
and heart failure between the study arms (Table 6).  
Our results suggested significantly reduction in systolic blood pressure in polypill arm at 
month 24 (p-value=0.01) (Table 7). The changes in systolic (p-value=0.08) and diastolic p-
value=0.09) blood pressure at the end of study were slightly greater in polypill arm when 
compared to minimal care arm. Changes in LDL-cholesterol were significantly greater in 
polypill arm both at month 24 and at the end of the study (p-value<0.01) (Table 7).     
Adverse events 
Figures 6 shows the frequencies of adverse events in polypill and minimal care arms. Overall, 
the frequency of adverse events was comparable between the two arms. We found decreasing 
trends in the frequencies of dyspepsia, cough and dizziness during the study period. The 
trends for cataract/vision loss and renal colic were increasing. The frequencies of adverse 
events and their trends were almost similar in polypill and minimal care arms. 
A total number of 21 cases of intracranial hemorrhages were ascertained during the 5 years 
follow up, including 10 participants (0.29%) in polypill arm and 11 participants (0.32%) in 
minimal care arm (p-value=0.82). 
The frequencies of physician-confirmed diagnosis of peptic ulcer disease were 34 (1.13%) 
and 35 (1.18%) in polypill and minimal care arms, respectively (p-value=0.86). The 
frequencies of physician-confirmed diagnosis of upper GI bleeding were 13 (0.43%) and 9 
(0.30%) in polypill and minimal care arms, respectively (p-value=0.40).  
Additional comparison with usual care arm 
In total, 12,715 participants were entered into the analysis of additional comparison in three 
groups including polypill arm (n=4,233), minimal care arm (n=4,177) and usual care group 
(n=4,305) (Supplementary Figure 2). During 60 months of follow-up 1,126 new MCVEs 
occurred among all 12,715 participants included in the additional comparison analysis, 
including 308, 404 and 414 in the polypill arm, minimal care arm, and usual care group, 
respectively. Table 8 and Figure 7 presents the results of Cox regression models. The results 
showed significant lower risk of MCVE in polypill arm compared to the usual care group 
(adjusted HR=0.79; 95%CI: 0.68-0.92). Our results showed no difference in the risk of MCVE 
between minimal care arm and usual care group. 
 
 
Discussion: 
The main aim of the PolyIran study was to assess the effect of a polypill (a fixed-dose 
combination pill comprising aspirin 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, 
and either enalapril 5 mg or valsartan 40 mg per day) on the risk of major cardiovascular 
events. To our knowledge, this is the first large-scale pragmatic trial with long term follow up 
to investigate the effects of a fixed-dose combination therapy on primary and secondary 
prevention of CVDs.  
Our results showed that once daily polypill for a period of 5 years in 50-75 years-old 
participants reduced the risk of MCVE by 34%. The most striking difference was seen by 
adherence to treatment. We found a greater reduction (57%) in the risk of MCVE in 
participants with high adherence to polypill tablet. These significant results were consistent 
among men and women, younger and older individuals, and those with or without preexisting 
hypertension or a high blood cholesterol level. The risk of both fatal and non-fatal ischemic 
heart disease and both fatal and non-fatal stroke decreased significantly in the polypill arm. 
Adverse events were comparable between the polypill arm and the minimal care arm, 
suggesting that polypill tablet could reduce cardiovascular outcomes without additional 
adverse events.  
Several similar trials were conducted on fixed-dose combination pills in different population, 
but most of them were focused on adherence to polypill intake and its effects on CVD risk 
factors not hard outcomes as in this study (major cardiovascular events) and most studies also 
had a shorter follow up than the 60 months of the PolyIran study.17,21,24,25  
The 34% reduced MCVE risk (57% reduction in those with high adherence)  confirms that 
such a polypill strategy could help achieve the United Nation SDG to reduce premature 
mortality due to CVD by at least a third before 2030.5 A polypill strategy should therefore be 
in the agenda of health policy makers, especially in low- and middle-income countries. 
The PolyIran study showed approximately 40% reduction in the risk of MCVE in individuals 
without a history of CVDs (primary prevention) and 20% in those with previous CVDs 
(secondary prevention); the difference not being statistically significant. Therefore, polypill 
strategy could be used for both primary and secondary prevention in such high-risk settings. 
The rationale behind using polypill for primary or secondary prevention of CVDs is not quite 
the same. One of the main aims for using polypill in secondary prevention is to increase 
adherence to multi-drug regimens in patients with established CVD. In the PURE study,26 4-5 
years after their cardiovascular events, more than 50% of patients (from 10% in high-income 
to >75% in low-income countries) were not taking any of the drugs recommended for 
secondary prevention.26 Similarly low drug adherence for secondary prevention of CVDs has 
been recently reported in the participants of the GCS in the northeast of Iran especially 
among participants with less education and lower socioeconomic status.27  
Using polypill strategy for primary prevention of CVD may be implemented at individual or 
population levels14,28. The individual level approach, participants are screened for risk factors 
of CVD and the polypill is administered to individuals whose risk score is over a threshold. 
But, this approach has major limitations including high screening costs and difficulties in 
developing prediction models for different type of risk factors and different population.29 
Therefore, it is recommended to consider a population-based strategy to reduce risk factor 
levels at population level28,30. It has been suggested that population level strategies using 
polypill for primary prevention of CVD may have a larger impact than focusing only on high-
risk individuals.31  
In the PolyIran study, we considered the population-based primary prevention strategy and 
our results confirmed the effectiveness of polypill for primary prevention of CVD at 
population level. 
Compared with the use of aspirin in secondary prevention among patients at high baseline 
risk of further MCVE, aspirin use for primary prevention of CVDs remain controversial due 
to its side effects mostly bleeding.14,32,33  A meta-analysis of aspirin use in primary prevention 
showed that aspirin, even less than 100 mg/d, is associated with approximately 11% 
reduction in cardiovascular events in both low- and high-risk populations, although the risk of 
major bleeding was increased.33 In our study, high-risk individuals for bleeding were 
ineligible and excluded from the trial23 and we found no significant increase in risk of GI or 
intracranial bleeding in the polypill group. Based on these rationales and specific 
considerations, a low-cost fixed-dose combination pill (production fee: 5 US cents per pill) 
including known medications for prevention of CVDs7,10,17,27,33,34 was produced and delivered 
free of charge for both primary  and secondary prevention groups.23   
 This study showed relatively high adherence to polypill tablet (median=80.5%) which 
remained stable through the study period. Improving adherence is one of the major benefits 
of polypill strategy and was considered as the main primary outcome in most of initial 
clinical trials on polypill.34,35  The high adherence may in part though be due to the PolyIran 
study being conducted within the well-established GCS with its good associated 
infrastructure and knowledgeable population.23 
Previous reports suggested that a 1% reduction in LDL-cholesterol gives a 1% decrease in the 
risk of atherosclerotic CVDs.36 Moderate-dose statin use (i.e., atorvastatin 20 mg/d) typically 
decreases LDL-cholesterol level by 30-49%.36 In our study, after 5 years, LDL-cholesterol 
level decreased by 35 mg/dl (30%) in the polypill arm, but the mean difference between two 
main arms was 19.5 mg/dl (17%). Healthy lifestyle education and likely use of LDL-
cholesterol lowering drugs in the minimal care arm could have contributed to the differential 
20 mg/dl reduction in LDL-cholesterol in this arm.  
A meta-analysis showed that every 10 mmHg reduction in systolic blood pressure reduced 
the risk of major CVD events by 20% in primary and secondary prevention individuals.37 In 
our study, the mean reduction in systolic blood pressure in the polypill arm was 5.6 mmHg 
but the mean difference between the polypill arm and minimal care arm was only 1.4 mmHg. 
These results could be due to the insufficient dosing of antihypertensive drugs. Our 
participants were almost healthy with normal BP, so we did not expect considerable decrease 
in blood pressure in our study. Likewise, in the HOPE-3 study, using candesartan and 
hydrochlorothiazide (16 and 12.5 mg per day, respectively), systolic blood pressure reduced 
by 6 mmHg in the context of primary prevention and was not associated with a lower rate of 
cardiovascular events, compared with placebo.38  
The results of additional non randomized comparisons showed significant reduction in the 
risk of MCVE in polypill arm when compared to the minimal care and usual care arms. It 
also showed that there were no significant differences in the risk of outcomes between 
minimal care arm and usual care group. This may partly be explained by implementation of 
cardiovascular diseases surveillance program in public health network in Iran during the last 
decade which is being conducted more rigorously during recent years as part of the national 
action plan for prevention and control of non-communicable diseases.39 The aim of this 
program is to identify high-risk individuals for CVD and to perform periodical assessment 
and referring the high-risk individuals to physician for monitoring and controlling the 
conditions. These programs are almost similar to the minimal care intervention of the 
minimal care arm of the PolyIran study. These national preventive services were routinely 
provided to all individuals in our study area including the participants of the polypill arm, 
minimal care arm as well as usual care arm. It is possible that the benefits of the polypill in 
populations where there are no similar preventive services may be bigger than those observed 
in this study. Therefore, this point should be taken into account during interpretation of the 
PolyIran results.   
This study has some limitations. First, we used only one fixed-dose combination pill for all 
participants, including primary and secondary prevention individuals. It seems that using 
flexible possibilities (i.e., different dosage levels for each drug and different combinations to 
tailor for specific clinical settings) could improve dug adherence and efficacy.27 Second, in 
the beginning of the study (involving 48 cluster, 2115 participants), the enrolment team was 
aware of the allocation of clusters. It could have affected the behaviors of the enrolling 
physicians, e.g. in applying the exclusion criteria more stringently to the polypill arm. 
Thereafter, enrolment team were blinded to cluster allocation. A subgroup analysis did not 
show a significant difference between participants with or without allocation concealment. 
Third, healthy lifestyle education (e.g., face-to-face interview and twice monthly short text 
messages) during the study could encourage participants in the minimal care arm to visit 
physicians and likely take medications, which could underestimate the size of the benefits of 
the polypill. Forth, the PolyIran study was conducted only on rural population and this point 
may affect the generalizability of our findings and should be considered in interpretation of 
our results.   
In conclusion, the PolyIran study, using fixed-dose combination of aspirin, atorvastatin, and 
two blood pressure lowering drugs was associated with a significant lower risk of major 
cardiovascular events in 50-75 year-old individuals. This pragmatic trial showed for the first 
time that using a low-cost polypill in a real-life setting could significantly reduce 
cardiovascular events and should now be considered an important step in applying the 
cardiovascular polypill strategy to eligible adults, broadly, especially in LMICs. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Table 1. Eligibility criteria in PolyIran study. All subjects in the polypill arm, minimal care arm and 
those receiving usual care were assessed for inclusion criteria but the exclusion criteria were only applied 
to the minimal care and polypill arms. 
Inclusion criteria 
 Age over 50 years old 
 Living in rural areas 
Exclusion criteria 
 Hypersensitivity to one of components of polypill (excluding cough due to enalapril) 
 History of angioedema 
 History of gastrointestinal bleeding or peptic ulcer disease within 3 months of eligibility assessment 
 History of stroke 
 Pregnancy or lactation 
 Bleeding disorders such as haemophilia 
 Regular anticoagulant use (excluding aspirin) 
 Alcohol consumption more than three times a day 
 Advanced liver diseases defined as history of chronic liver disease and platelet count lower than 100,000/ml at the time of 
eligibility assessment 
 Uncontrolled seizures defined as history of any seizure episode within 2 years of eligibility assessment either on or off the 
anticonvulsant treatment 
 Presence of any of the following in asthmatic patient: 
a. Daily symptoms 
b. Night-time symptoms _1 night per week 
c. History of nasal polyposis 
d. Symptoms attributed to rhinitis without evidence of upper respiratory tract infection 
 History of gout 
 Serum creatinine >2 mg/dl 
 Glomerular filtration rate (GFR) <30 ml/min 
 Haemoglobin <10 mg/dl in females and <11 mg/dl in males 
 Systolic blood pressure <90mmHg and diastolic blood pressure <60 mmHg 
 Medical/psychiatric comorbidities potentially affecting the adherence of the participants: 
a. Major depression disorder, dementia, schizophrenia, manic-depressive bipolar disorder and other disorders with 
presentation of psychosis 
b. Cognitive impairments 
c. Blindness 
d. Inability to do diurnal activities independently, e.g. wheelchair-bound patients 
e. Disorientation with the study and its goals 
 Unavailability of the subjects 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Baseline Characteristics of participants in polypill and minimal care arms in total and by the status of allocation 
concealment 
 Clusters enrolled without 
allocation concealment 
 Clusters enrolled with 
allocation concealment 
 Total 
Characteristics Polypill  
Arm 
(n = 1070) 
Minimal care 
Arm 
(n = 766) 
 Polypill  
Arm 
(n = 2351) 
Minimal care 
Arm 
(n = 2651) 
 Polypill  
Arm 
(n = 3421) 
Minimal care 
Arm 
(n = 3417) 
Gender, No. (%) 
Male 
Female 
 
502 (46.9) 
568 (53.1) 
 
376 (49.1) 
390 (50.9) 
  
1158 (49.3) 
1193 (50.7) 
 
1362 (51.4) 
1289 (48.6) 
  
1660 (48.5) 
1761 (51.5) 
 
1738 (50.9) 
1679 (49.1) 
Pre-existing CVD, No. (%) 115 (10.7) 82 (10.7) 
  
273 (11.6) 
 
267 (10.1) 
 
338 (11.3) 349 (10.2) 
Pre-existing HTN, No. (%) 501 (46.8) 314 (41.0) 
  
1175 (50.0) 
 
1382 (52.0) 
 
1676 (49) 1696 (49.6) 
Pre-existing DM, No. (%) 181 (16.9) 114 (14.9) 
  
316 (13.4) 
 
418 (15.8) 
 
497 (14.5) 532 (15.6) 
Age group, No (%) 
<=65 
>65 
 
918 (85.8) 
152 (14.2) 
 
650 (84.9) 
116 (15.1) 
  
1895 (80.6) 
456 (19.4) 
 
2129 (80.3) 
522 (19.7) 
  
2813 (82.2) 
608 (17.8) 
 
2779 (81.3) 
638 (18.7) 
Cholesterol level, No. (%) 
<=198 mg/dL 
>198 mg/dL 
 
563 (52.6) 
507 (47.4) 
 
355 (46.3) 
411 (53.7) 
  
1148 (48.8) 
1202 (51.1) 
 
1338 (50.5) 
1313 (49.5) 
  
1711 (50.0) 
1709 (50.0) 
 
1693 (49.5) 
1724 (50.5) 
Smoking ever, No. (%) 
Yes 
No 
 
45 (4.2) 
1025 (95.8) 
 
62 (8.1) 
704 (91.9) 
  
90 (3.8) 
2261 (96.2) 
 
124 (4.7) 
2527 (95.3) 
  
135 (3.9) 
3286 (96.1) 
 
186 (5.4) 
3231 (94.6) 
Ethnicity, No. (%) 
Turkmen 
Non-Turkmen 
 
885 (82.7) 
185 (17.3) 
 
628 (82.1) 
137 (17.9) 
  
1998 (85.0) 
353 (15.0) 
 
2111 (79.6) 
540 (20.4) 
  
2883 (84.3) 
538 (15.7) 
 
2739 (80.2) 
677 (19.8) 
Low-density lipoprotein 
cholesterol, mean (95%CI), 
mg/dL 
115.0  
(112.0-118.0) 
119.2 
(113.8-124.7) 
 118.2 
(115.8-120.6) 
116.3 
(113.1-119.5) 
 117.21  
(115.24-119.18) 
116.96  
(114.18-119.74) 
Body mass index, mean 
(95%CI), kg/m2 
27.0  
(26.4-27.6) 
26.5  
(25.6-27.5) 
 26.4 
(26.0-26.9) 
26.4 
(26.0-26.8) 
 26.62  
(26.29-26.96) 
26.45  
(26.08-26.81) 
 Table 3. Hazard ratios and 95% confidence intervals for comparing major cardiovascular events 
(MCVE) between polypill and minimal care arms 
 Polypill 
arm; 
No./Total  
(%) 
Minimal 
care arm; 
No./Total  
(%) 
HR 
(95% CI) 
Adjusted HR  
(95% CI) 
P-value  
for 
interaction
Study arms 202/3421 
(5.9) 
301/3417 
(8.8) 
0.66  
(0.55-0.79) 
0.66  
(0.55-0.80) 
- 
Gender 
Male 
 
 
Female 
 
 
107/1660 
(6.45) 
 
95/1761  
(5.39) 
 
 
179/1738 
(10.30) 
 
122/1679 
(7.27) 
 
0.61  
(0.48-0.78) 
 
0.74  
(0.55-0.99) 
 
 
0.60  
(0.47-0.77) 
 
0.74  
(0.55-0.99) 
 
 
 
0.29 
Age group 
≤65 years 
 
 
>65 years 
 
145/2813 
(5.15) 
 
57/608  
(9.38) 
 
211/2779 
(7.59) 
 
90/638  
(14.11) 
 
0.67  
(0.53-0.84) 
 
0.65  
(0.46-0.92) 
 
0.66  
(0.53-0.83) 
 
0.63  
(0.44-0.90) 
 
 
 
0.90 
Pre-existing MCVE 
Yes 
 
 
No 
 
 
66/388  
(17.01) 
 
136/3033 
(4.48) 
 
 
72/349  
(20.63) 
 
229/3068 
(7.46) 
 
0.81 
(0.58-1.13) 
 
0.59  
(0.47-0.73) 
 
0.80  
(0.57-1.12) 
 
0.61  
(0.49-0.75) 
 
 
 
0.19 
Allocation concealment 
Without concealment 
 
 
Concealed allocation 
 
 
49/1070  
(4.58) 
 
153/2351 
(6.51) 
 
 
61/766  
(7.96) 
 
240/2651 
(9.05) 
 
0.59  
(0.37-0.95) 
 
0.71  
(0.58-0.87) 
 
0.53  
(0.33-0.85) 
 
0.73 
(0.61-0.86) 
 
 
 
0.23 
Pre-existing HTN 
Yes 
 
 
No 
 
134/1676 
(8.00) 
 
68/1745  
(3.90) 
 
 
202/1696 
(11.91) 
 
99/1721  
(5.75) 
 
0.65  
(0.52-0.82) 
 
0.67  
(0.49-0.93) 
 
0.64  
(0.50-0.81) 
 
0.67  
(0.48-0.93) 
 
 
 
0.85 
 
 
Pre-existing DM 
Yes 
 
 
No 
 
 
59/497  
(11.87) 
 
143/2923 
(4.89) 
 
 
76/532  
(14.29) 
 
225/2883 
(7.80) 
 
0.82  
(0.58-1.15) 
 
0.61  
(0.50-0.76) 
 
0.76  
(0.53-1.08) 
 
0.62  
(0.50-0.77) 
 
 
 
0.36 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline Cholesterol level 
≤198 mg/dL 
 
 
>198 mg/dL 
 
 
95/1711  
(5.55) 
 
107/1709 
(6.26) 
 
142/1693 
(8.39) 
 
159/1724 
(9.22) 
 
0.65  
(0.50-0.85) 
 
0.67  
(0.52-0.85) 
 
0.62  
(0.47-0.82) 
 
0.69  
(0.53-0.88) 
 
 
 
0.69 
Smoking ever 
Yes 
 
 
No 
 
10/135  
(7.41) 
 
192/3286 
(5.84) 
 
20/186  
(10.75) 
 
281/3231 
(8.70) 
 
0.68  
(0.32-1.45) 
 
0.66  
(0.54-0.80) 
 
0.68 
(0.31-1.47) 
 
0.66  
(0.55-0.80) 
 
 
0.95 
Adherence 
Polypill arm (High) 
Polypill arm (Medium/low) 
            Minimal care arm 
 
86/2144 (4.0) 
116/1277 (9.08) 
301/3417 (8.8) 
 
0.44 (0.34-0.56) 
1.04 (0.83-1.30) 
Ref. 
 
0.43 (0.33-0.55) 
1.08 (0.86-1.35) 
Ref. 
 
 
- 
- MCVE included either hospitalization for acute coronary syndrome (non-fatal myocardial infarction and 
unstable angina), fatal myocardial infarction, sudden death, heart failure, coronary artery 
revascularization procedures, non-fatal and fatal stroke. 
- Hazard ratios (HR) and 95% confidence intervals were obtained using Cox regression models with 
shared frailty.  
- Adjusted models are adjusted for age, gender, preexisting major cardiovascular events, diabetes 
mellitus, and hypertension. For subgroup analyses, the subgroup variable was not entered into the 
model. 
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Figure 4. Cumulative Hazard function for major cardiovascular events (MCVE) as primary outcomes in
the study arms in participants without pre-existing CVD (A) (primary prevention group) and with pre-
existing CVD (B) (secondary prevention group). (The clustering effects were adjusted using frailty model)
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Figure 3. Cumulative Hazard function for major cardiovascular events (MCVE) in the two arms 
(The clustering effects were adjusted using frailty model) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Hazard ratios and 95% confidence intervals for comparing major cardiovascular events 
(MCVE) between polypill and minimal care arms by duration of follow up interval 
 Follow up time 
(Persons-month) 
MCVE,  
No./Total (%) 
HR 
(95% CI) 
Adjusted HR  
(95% CI) 
Follow up intervals 
Month 0- Month 60 
Polypill arm 
Minimal care arm 
Month 13- Month 60 
Polypill arm 
Minimal care arm 
Month 25- Month 60 
Polypill arm 
Minimal care arm 
Month 37- Month 60 
Polypill arm 
Minimal care arm 
 
 
200237.5 
197105.5 
 
199977.2 
196730.8 
 
199115.5 
195599.9 
 
197655.3 
193581.3 
 
 
202/3421 (5.9) 
301/3417 (8.8) 
 
160/3379 (4.7) 
246/3362 (7.3) 
 
114/3333 (3.4) 
189/3305 (5.7) 
 
67/3286 (2.0) 
123/3239 (3.8) 
 
 
0.66 (0.55-0.79) 
Ref. 
 
0.63 (0.52-0.77) 
Ref. 
 
0.58 (0.46-0.74) 
Ref. 
 
0.52 (0.39-0.70) 
Ref. 
 
 
0.65 (0.54-0.88) 
Ref. 
 
0.64 (0.52-0.78) 
Ref. 
 
0.59 (0.46-0.75) 
Ref. 
 
0.52 (0.39-0.70) 
Ref. 
- MCVE included either hospitalization for acute coronary syndrome (non-fatal myocardial infarction and 
unstable angina), fatal myocardial infarction, sudden death, heart failure, coronary artery revascularization 
procedures, non-fatal and fatal stroke. 
- Hazard ratios (HR) and 95% confidence intervals were obtained using Cox regression models with shared 
frailty.  
- All models are adjusted for age, gander, preexisting major cardiovascular events, diabetes mellitus, and 
hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Adherence to polypill tablet in participants of the PolyIran study by follow up month 
 
 
Table 5. Predictors of high adherence (>=70%) to polypill tablet in the PolyIran study  
Covariates high adherence, 
No./Total (%) 
Odds Ratio (95% CI)* Adjusted Odds** 
Ratio (95% CI) 
Gender 
Male 
Female 
 
1093/1660 (65.8) 
1051/1761 (59.7) 
 
1.28 (1.10-1.48) 
Ref. 
 
1.39 (1.19-1.62) 
Ref. 
Pre-existing CVD 
Yes 
No 
 
225/388 (58.0) 
1919/3033 (63.3) 
 
0.78 (0.63-0.98) 
Ref. 
 
0.72 (0.57-0.90) 
Ref. 
Pre-existing HTN 
Yes 
No 
 
1114/1676 (66.5) 
1030/1745 (59.0) 
 
1.48 (1.27-1.72) 
Ref. 
 
1.57 (1.34-1.83) 
Ref. 
Smoking, No. (%) 
Yes 
No 
 
73/135 (54.1) 
2071/3286 (63.0) 
 
0.78 (0.54-1.13) 
Ref. 
 
0.68 (0.46-0.99) 
Ref. 
Pre-existing DM 
Yes 
No 
 
313/497 (63.0) 
1830/2923 (62.6) 
 
1.06 (0.86-1.31) 
Ref. 
- 
Age group, No (%) 
≤65 
>65 
 
1764/2813 (62.7) 
380/608 (62.5) 
 
1.00 (0.82-1.21) 
Ref. 
- 
Cholesterol level, No. (%) 
≤198 mg/dL 
>198 mg/dL 
 
1058/1711 (61.8) 
1085/1709 (63.5) 
 
0.93 (0.80-1.08) 
Ref. 
- 
Ethnicity, No. (%) 
Turkmen 
Non-Turkmen 
 
1794/2883 (62.2) 
650/538 (65.1) 
 
0.99 (0.74-1.32) 
Ref. 
- 
* All odds ratios were obtained using mixed-effects logistic regression models 
** Adjusted for gender, smoking, pre-existing major cardiovascular events and hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Hazard ratios and 95% confidence intervals for comparing the risks of secondary 
outcomes between polypill and minimal care arms 
 Polypill 
arm; 
No./Total  
(%) 
Minimal 
care arm; 
No./Total  
(%) 
HR* 
(95% CI) 
Adjusted HR**  
(95% CI) 
P-value  
 
Fatal ischemic heart diseases 21/3421 
(0.61) 
41/3417 
(1.20) 
0.50 (0.29-0.85) 0.51 (0.30-0.87) 0.01 
Non-fatal ischemic heart 
diseases 
127/3421 
(3.71) 
169/3417 
(4.95) 
0.75 (0.59-0.96) 0.74 (0.58-0.96) 0.02 
Fatal stroke 8/3421 
(0.23) 
21/3417 
(0.61) 
0.37 (0.17-0.81) 0.38 (0.18-0.82) 0.01 
Non-fatal stroke 17/3421 
(0.50) 
39/3417 
(1.14) 
0.43 (0.23-0.81) 0.44 (0.23-0.82) 0.01 
Sudden death 19/3421 
(0.56) 
28/3417 
(0.82) 
0.68 (0.36-1.28) 0.69 (0.36-1.32) 0.26 
Heart failure 15/3421 
(0.44) 
18/3417 
(0.53 
0.83 (0.42-1.65) 0.80 (0.40-1.59) 0.53 
Non-cardiovascular causes of 
death 
149/3421 
(4.35) 
123/3417 
(3.60) 
1.23 (0.95-1.58) 1.26 (0.98-1.62) 0.07 
Overall mortality 202/3421 
(5.90) 
222/3417 
(6.50) 
0.90 (0.74-1.09) 0.93 (0.77-1.11) 0.43 
* Hazard ratios (HR) and 95% confidence intervals were obtained using Cox regression models with shared 
frailty 
** All models are adjusted for age, gender, preexisting major cardiovascular events, diabetes mellitus, and 
hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7. Effects of polypill tablet on blood pressure and LDL-cholesterol levels as secondary 
outcomes of the PolyIran study  
 Polypill arm; 
Mean (95%CI) 
Minimal care arm; 
Mean (95%CI) 
Mean difference 
(95% CI) 
P-value*  
 
Change in systolic blood 
pressure (mmHg) from 
baseline to 
Month 24 
 
 
Month 60 
 
 
-2.46  
(-3.26 to -1.66) 
 
-5.58 
(-6.41 to -4.75) 
 
 
0.59 
(-0.22 to 1.40) 
 
-4.18 
(-4.99 to -3.37) 
 
 
-3.05 
(-4.19 to -1.91) 
 
-1.40 
(-2.56 to -0.24) 
 
 
0.01 
 
 
0.08 
Change in diastolic blood 
pressure (mmHg) from 
baseline to 
Month 24 
 
 
Month 60 
 
 
-0.67 
(-1.15 to -0.18) 
 
-4.31 
(-4.80 to -3.83) 
 
 
0.07 
(-0.40 to 0.55) 
 
-2.91 
(-3.41 to -2.41) 
 
 
-0.74 
(-1.43 to -0.06) 
 
-1.40 
(-2.10 to -0.70) 
 
 
0.30 
 
 
0.09 
Changes in LDL-C** (mg/dl) 
from baseline to 
Month 24 
 
 
Month 60 
 
 
 
-26.73 
(-28.04 to -25.41) 
 
-35.39 
(-36.65 to -34.12) 
 
 
-2.08 
(-3.31 to -0.84) 
 
-15.85 
(-17.13 to -14.57) 
 
 
-24.65 
(-26.45 to -22.85) 
 
-19.54 
(-21.33 to -17.74) 
 
 
<0.01 
 
 
<0.01 
* P-values were obtained using mixed effects linear regression models (with log transformation for variables 
with non-normal distribution). All models are adjusted for age, gender, preexisting major cardiovascular events, 
diabetes mellitus, and hypertension 
** Low density lipoprotein cholesterol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Frequency of adverse events in Polypill and minimal care arms by follow up visits 
  
 
 
 
 
 
 
 
 
 
 
Table 8. Hazard ratios and 95% confidence intervals for comparing major cardiovascular events 
(MCVE) between polypill arm, minimal care arm and usual care group (additional comparison) 
 No. (%) of 
subcategory in 
the study arm  
MCVE,  
No./Total (%) 
HR 
(95% CI) 
Adjusted HR  
(95% CI) 
Study arms 
Polypill arm 
Minimal care arm  
Usual care group 
- 
 
308/4233 (7.3) 
404/4177 (9.7) 
414/4305 (9.6) 
 
0.73 (0.63-0.84) 
0.98 (0.85-1.12) 
Ref. 
 
0.79 (0.68-0.92) 
1.05 (0.91-1.21) 
Ref. 
Gender 
Male 
Polypill arm 
Minimal care arm 
Usual care group 
Female 
Polypill arm 
Minimal care arm 
Usual care group 
 
 
2056 (48.6) 
2077 (49.7) 
1583 (36.8) 
 
2177 (51.4) 
2100 (50.3) 
2722 (63.2) 
 
 
159/2056 (7.73) 
228/2077 (10.98) 
164/1583 (10.36) 
 
149/2177 (6.84) 
176/2100 (8.38) 
250/2722 (9.18) 
 
 
0.71 (0.57-0.89) 
1.04 (0.83-1.28) 
Ref. 
 
0.71 (0.58-0.88) 
0.89 (0.73-1.07) 
Ref. 
 
 
0.78 (0.63-0.98) 
1.12 (0.90-1.38) 
Ref. 
 
0.80 (0.65-0.99) 
0.99 (0.81-1.20) 
Ref. 
Age group, No (%) 
≤65 
Polypill arm 
Minimal care arm 
Usual care group 
>65 
Polypill arm 
Minimal care arm 
Usual care group 
 
 
3357 (79.3) 
3276 (78.4) 
2927 (68.0) 
 
876 (20.7) 
901 (21.6) 
1378 (32.0 
 
 
198/3357 (5.90) 
257/3276 (7.84) 
218/2927 (7.45) 
 
110/876 (12.56) 
147/901 (16.32) 
196/1378 (14.22) 
 
 
0.77 (0.63-0.93) 
1.02 (0.85-1.23) 
Ref. 
 
0.84 (0.66-1.07) 
1.12 (0.91-1.38) 
Ref. 
 
 
0.76 (0.62-0.92) 
1.01 (0.84-1.21) 
Ref. 
 
0.84 (0.66-1.06) 
1.11 (0.89-1.38) 
Ref. 
- MCVE included either hospitalization for acute coronary syndrome (non-fatal myocardial infarction and 
unstable angina), fatal myocardial infarction, sudden death, heart failure, coronary artery revascularization 
procedures, non-fatal and fatal stroke 
- Hazard ratios (HR) and 95% confidence intervals were obtained using Cox regression models with shared 
frailty  
- All models are adjusted for age and gander, except the variable for which stratification is done. 
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Figure 7. Cumulative Hazard function for major cardiovascular events (MCVE) in polypill arm, 
minimal care arm and usual care group of the PolyIran study (additional comparison). (The 
clustering effects were adjusted using frailty model) 
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